Department of Clinical Science, National Hospital Organization Okayama Medical Center.
Circ J. 2018 Apr 25;82(5):1222-1230. doi: 10.1253/circj.CJ-18-0258. Epub 2018 Apr 17.
In the past 5 years, balloon pulmonary angioplasty (BPA) for patients with chronic thromboembolic pulmonary hypertension (CTEPH) who are deemed inoperable has undergone significant refinement. As a result, the procedure is now used worldwide and has become a promising therapeutic option for those patients. However, pulmonary endarterectomy remains the gold standard treatment for patients with CTEPH because the techniques and strategies for BPA are not yet unified. The best therapeutic option for each patient should be determined based on discussion among a multidisciplinary team of experts. For BPA to become an established treatment for CTEPH, further data are needed. This review summarizes the techniques and strategies of BPA at present and discusses the future development of the procedure.
在过去的 5 年中,针对被认为无法手术的慢性血栓栓塞性肺动脉高压(CTEPH)患者的球囊肺动脉成形术(BPA)经历了显著的改进。因此,该手术现在在全球范围内得到应用,并且已成为这些患者有前途的治疗选择。但是,肺血管内膜切除术仍然是 CTEPH 患者的金标准治疗方法,因为 BPA 的技术和策略尚未统一。每个患者的最佳治疗选择应基于多学科专家团队的讨论来确定。为了使 BPA 成为 CTEPH 的既定治疗方法,还需要进一步的数据。本综述总结了目前 BPA 的技术和策略,并讨论了该手术的未来发展。